Sign in →

Test Code MMLRG Antimicrobial Susceptibility, Acid-Fast Bacilli, Rapidly Growing, Varies

Infectious

Reporting Name

Susc, AFB, Rapidly Growing

Useful For

Determination of susceptibility of rapidly growing mycobacteria to the antimicrobial agents on the test panel

Additional Tests

Test ID Reporting Name Available Separately Always Performed
SRG Susceptibility Rapid Grower No, (Bill Only) Yes

Testing Algorithm

When this test is ordered, rapid grower susceptibility will be performed at an additional charge.

Method Name

Minimum Inhibitory Concentration (MIC) by Microtiter Broth Dilution Method

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Varies


Additional Testing Requirements


If organism identification is not provided, CTB / Mycobacteria and Nocardia Culture, Varies or CTBID / Culture Referred for Identification, Mycobacterium and Nocardia, Varies must also be ordered and will be charged separately.



Shipping Instructions


1. For shipping information see Infectious Specimen Shipping Guidelines

2. Place specimen in a large infectious container and label as an etiologic agent/infectious substance.



Necessary Information


1. Specimen source is required.

2. Organism identification is required unless either CTB / Mycobacteria and Nocardia Culture, Varies or CTBID / Culture Referred for Identification, Mycobacterium and Nocardia, Varies is also ordered.

3. Identification to the species level is required for Mycobacterium species for the correct antimicrobial susceptibility drug panel to be selected. Identification to the genus level is sufficient for Nocardia species and other aerobic actinomycetes (eg, Gordonia species, Rhodococcus species).



Specimen Required


Specimen Type: Organism

Supplies: Infectious Container, Large (T146)

Container/Tube: Middlebrook 7H10 agar slant or other appropriate media

Specimen Volume: Pure isolate

Collection Instructions: Organism must be in pure culture, actively growing.


Specimen Minimum Volume

See Specimen Required

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Ambient (preferred)
  Refrigerated 

Reject Due To

Agar plate Reject

Reference Values

Interpretive criteria and reporting guidelines are followed using the Clinical Laboratory Standards Institute (CLSI) M24S document.

Day(s) Performed

Monday through Sunday

CPT Code Information

87186

LOINC Code Information

Test ID Test Order Name Order LOINC Value
MMLRG Susc, AFB, Rapidly Growing 29579-0

 

Result ID Test Result Name Result LOINC Value
MMLRG Susc, AFB, Rapidly Growing 29579-0

Clinical Information

There are more than 100 species of rapidly growing mycobacteria and many are significant human pathogens (eg, Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium fortuitum). Rapidly growing mycobacteria cause a variety of infections including pulmonary infections, skin and soft tissue infections, and disseminated disease. Antimicrobial susceptibility testing of clinically significant rapidly growing mycobacteria is important to help guide patient care.

 

Antimicrobials tested in this assay are amikacin, cefoxitin, ciprofloxacin, clarithromycin, clofazimine, doxycycline, imipenem, linezolid, moxifloxacin, tigecycline, tobramycin, and trimethoprim/sulfamethoxazole.

Interpretation

Results are reported as the minimum inhibitory concentration in micrograms/mL. Interpretive criteria (susceptible, intermediate, or resistant) are reported according the Clinical and Laboratory Standards Institute guidelines.

Method Description

The method employed in this assay is broth microtiter dilution using a commercially available RAPMYCO2 plate. Antimicrobials included in the assay are tested according to CLSI guidelines.(Clinical and Laboratory Standards Institute [CLSI]. Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. CLSI standard M24. Clinical and Laboratory Standards Institute [CLSI]. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. CLSI supplement M24S)

Report Available

12 to 28 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.